43 related articles for article (PubMed ID: 15765311)
1. Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients.
Goutelle S; Baudry T; Gagnieu MC; Boibieux A; Livrozet JM; Peyramond D; Chidiac C; Tod M; Ferry T;
Antimicrob Agents Chemother; 2013 Jan; 57(1):517-23. PubMed ID: 23147727
[TBL] [Abstract][Full Text] [Related]
2. Atazanavir: clinical use.
Bartlett JG
Hopkins HIV Rep; 2003 Jul; 15(4):3-4. PubMed ID: 14696561
[No Abstract] [Full Text] [Related]
3. Drug profile: atazanavir (Reyataz, ATV).
Pham PA
Hopkins HIV Rep; 2003 Jul; 15(4):4-5. PubMed ID: 14696562
[No Abstract] [Full Text] [Related]
4. Predictors of virological response to atazanavir in protease inhibitor-experienced patients.
Barrios A; Rendón AL; Gallego O; Martín-Carbonero L; Valer L; Ríos P; Maida I; García-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V
HIV Clin Trials; 2004; 5(4):201-5. PubMed ID: 15472794
[TBL] [Abstract][Full Text] [Related]
5. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
[TBL] [Abstract][Full Text] [Related]
6. Atazanavir: the advent of a new generation of more convenient protease inhibitors.
Barreiro P; Rendón A; Rodríguez-Nóvoa S; Soriano V
HIV Clin Trials; 2005; 6(1):50-61. PubMed ID: 15765311
[TBL] [Abstract][Full Text] [Related]
7. Atazanavir: a review of its use in the management of HIV-1 infection.
Croom KF; Dhillon S; Keam SJ
Drugs; 2009 May; 69(8):1107-40. PubMed ID: 19496633
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of atazanavir in treatment-naive patients].
Moreno S; Hernández B; Dronda F
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
[TBL] [Abstract][Full Text] [Related]
9. [Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].
Rivero A; Camacho A; Pérez-Camacho I; Torre-Cisneros J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():45-8. PubMed ID: 20116617
[TBL] [Abstract][Full Text] [Related]
10. Atazanavir: simplicity and convenience in different scenarios.
Pérez-Elías MJ
Expert Opin Pharmacother; 2007 Apr; 8(5):689-700. PubMed ID: 17376023
[TBL] [Abstract][Full Text] [Related]
11. Atazanavir: a new protease inhibitor to treat HIV infection.
Musial BL; Chojnacki JK; Coleman CI
Am J Health Syst Pharm; 2004 Jul; 61(13):1365-74. PubMed ID: 15287232
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
